ArQule regains AKT rights from Daiichi Sankyo
This article was originally published in Scrip
Executive Summary
ArQule's investors were unfazed on the day after Easter by the company's announcement that it had regained worldwide development and commercialization rights to its AKT technology, including the program's lead compound ARQ 092, from Daiichi Sankyo.